Mesoblast Ltd. (MESO), which is developing off-the-shelf cellular medicines for life-threatening inflammatory conditions, is planning to file a Biologics License Application for Ryoncil with the FDA next week.
Ryoncil is being developed for the treatment of children with steroid-refractory acute graft versus host disease (SR-aGVHD). It comprises of culture-expanded mesenchymal stem cells derived from the bone marrow of an unrelated donor.
Steroid-resistant or steroid-refractory acute graft-versus-host disease (SR-aGVHD) is one of the significant complications that can arise following allogeneic hematopoietic cell transplantation.
MESO has traded in a range of $1.61 to $10.24 in the last 1 year. The stock closed Friday's trading (June 28, 2024) at $6.81, down 0.58%.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.